NASDAQ: ITOS - iTeos Therapeutics, Inc.

Yield per half year: -52.15%
Sector: Healthcare

Share chart iTeos Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Iteos Therapeutics, Inc., биофармацевтическая компания клинической стадии, занимается открытием и разработкой иммуноонкологических терапевтических средств для пациентов.

more details
Ассортимент продукции компании включает инупаденант, низкомолекулярный антагонист антагонистов аденозина A2AR, который находится на второй фазе клинических испытаний; и EOS-448, антагонист TIGIT или Т-клеточного иммунорецептора с доменами Ig и ITIM, который находится на стадии клинических испытаний 1/2, а также используется для взаимодействия с гамма-рецептором Fc или Fc?R для активации дендритных клеток, естественные клетки-киллеры и макрофаги, а также для стимуляции антителозависимой клеточной цитотоксичности или активности ADCC. Компания Iteos Therapeutics, Inc. была основана в 2011 году и имеет штаб-квартиру в Уотертауне, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-07-24
ISIN US46565G1040
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.iteostherapeutics.com
Цена ао 7.8
Change price per day: 0% (7.8)
Change price per week: -0.3831% (7.83)
Change price per month: +1.56% (7.68)
Change price per 3 month: -17.2% (9.42)
Change price per half year: -52.15% (16.3)
Change price per year: -29.35% (11.04)
Change price per 3 year: -81.86% (43.01)
Change price per 5 year: 0% (7.8)
Change price per 10 year: 0% (7.8)
Change price per year to date: +8.03% (7.22)
All parameters

Underestimation

Title Value Grade
P/S 30.81 1
P/BV 0.6746 10
P/E 7.42 10
EV/EBITDA -0.9925 0
Total: 6.25

Efficiency

Title Value Grade
ROA, % -16.87 0
ROE, % -19.58 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0421 10
Total: 8.4

Growth impulse

Title Value Grade
Yield Revenue, % -96.34 0
Yield Ebitda, % 595.55 10
Yield EPS, % 39.04 5
Total: 7
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
23.08.2023 25.08.2023 Boxer Capital, LLC
 Sale 16.26 5 691 000 350000 0 -0.99 link

Institutions Volume Share, %
Blackrock Inc. 4463306 12.48
RA Capital Management, L.P. 4417259 12.35
Mpm Asset Management, LLC 2738785 7.66
Boxer Capital, LLC 2154058 6.02
State Street Corporation 1827391 5.11
BVF Inc. 1810835 5.06
Vanguard Group, Inc. (The) 1772989 4.96
BioImpact Capital LLC 1745943 4.88
Citadel Advisors Llc 1443500 4.04
Candriam Luxembourg S.C.A. 739517 2.07

ETF Share, % Profitability for 1 year, % Dividends, %
Range Cancer Therapeutics ETF 1.47631 47.24 0.11955
Virtus LifeSci Biotech Clinical Trials ETF 0.54714 63.04 0.33
iShares Micro-Cap ETF 0.07536 17.09 1.54048
WisdomTree U.S. SmallCap Fund 0.05712 15.03 1.80258
Avantis U.S Small Cap Equity ETF 0.04658 27.77 1.68271
Principal Healthcare Innovators ETF 0.04256 618.5 0.8416
Future Tech ETF 0.04256 426.34 0.8416
Invesco Nasdaq Biotechnology ETF 0.04032 28.58 0.8565
Direxion Daily S&P Biotech Bull 3x Shares 0.03513 4067.92 0.25924
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.03293 17.58 1.75869
iShares MSCI USA Small-Cap Min Vol Factor ETF 0.03005 18.2 1.66828
ProShares Ultra Nasdaq Biotechnology 0.02869 51.7 0.85651
Vanguard Russell 2000 ETF 0.02 17.16 1.48801
Dimensional U.S. Targeted Value ETF 0.01839 26.01 1.93487
Schwab U.S. Small-Cap ETF 0.00864 17.47 1.51433
ProShares UltraPro Russell2000 0.00631 89.82 1.47873
Fidelity MSCI Health Care Index ETF 0.00411 3 1.46057
Dimensional U.S. Core Equity 2 ETF 0.00348 30.76 1.47098
Dimensional US Small Cap Value ETF 0.00186 25.85 1.97866
ProShares Hedge Replication ETF 0.00184 5.92 1.47892
Dimensional US Core Equity Market ETF 0.00116 30.98 1.40618
Avantis U.S. Equity ETF 0.00081 23.04 1.59151
SPDR Portfolio MSCI Global Stock Market ETF 0.00078 17.99 2.19607
Schwab U.S. Broad Market ETF 0.00055 24.86 1.43354
iShares Russell 3000 ETF 0.0005 24.83 1.43482
Dimensional U.S. Equity ETF 0.00046 31.53 1.3557
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Dr. Michel Detheux Ph.D. President, CEO & Director 922.38k 1967 (58 years)
Mr. Matthew A. Call M.B.A. Chief Operating Officer 638.55k 1973 (52 years)
Mr. Matthew Gall Chief Financial Officer 628.45k 1977 (48 years)
Dr. Yvonne McGrath Ph.D. Chief Scientific Officer N/A 1974 (51 year)
Ms. Adi Osovsky Executive Vice President of Legal N/A
Mr. Philippe Brantegem Executive Vice President of Human Resources
Dr. David Feltquate M.D., Ph.D. Chief Medical Officer

Address: United States, Watertown. MA, 321 Arsenal Street - open in Google maps, open in Yandex maps
Website: https://www.iteostherapeutics.com